By Fineline Cube 
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in‑house drug BIOS‑0629, a second‑generation Nuclear Export Protein 1 (XPO1) inhibitor.
Partnership Structure
| Element | Detail |
|---|---|
| Up‑front Payment | 30 million CNY (≈ US$4.3 M) |
| Milestone Payments | 300 million CNY (≈ US$43 M) tied to R&D milestones |
| Revenue Share | Bio‑Sincerity to receive 10 % of post‑launch sales in Greater China |
| Timeline | Collaborative product is slated for market launch pending regulatory approval |
Zhongshen Innovation’s commitment underscores confidence in BIOS‑0629’s potential to bridge the current gap between the first‑generation XPO1 inhibitor (Selenixor) and the unmet need for safer, solid‑tumor‑active therapeutics.
Product Profile – BIOS‑0629
- Class: 1 innovative drug
- Mechanism: Second‑generation XPO1 inhibitor – improves safety profile while preserving anti‑tumor potency compared with Selenixor.
- Indication Horizon: Initially targeted at hematologic malignancies (mirroring the first‑generation approval) with a strategic expansion into solid tumor indications (e.g., non‑small cell lung cancer, colorectal cancer).
- Development Status: Self‑developed by Bio‑Sincerity across pre‑clinical and first‑in‑human phases; R&D milestones will trigger subsequent payments under the agreement.
Market Context
Only one XPO1 inhibitor, Selenixor (first‑generation), is currently approved worldwide. BIOS‑0629 seeks to position itself as the next‑generation alternative, potentially offering:
- Reduced adverse events (e.g., neutropenia, hepatotoxicity)
- Broadening of therapeutic area into solid tumors, where XPO1 inhibition remains largely unexplored but highly promising.
Investor Impact
While BIOS‑0629 is still a pre‑clinical asset, the agreement represents a significant financial and strategic boost for Bio‑Sincerity:
- Direct infusion of US$4.3 M upfront capital.
- Potential long‑term upside via 10 % revenue share and future milestone inflows totaling US$43 M.
- Enhanced profile among Hangzhou‑based biotech firms navigating a competitive oncology landscape.
Forward‑Looking Statements
This briefing contains forward‑looking statements about the partnership, product development, and potential regulatory outcomes. Actual results may differ materially due to market and regulatory uncertainties.-Fineline Info & Tech